Porustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR were 38.5% and 69.2% in neuroendocrine carcinoma (NEC) patients The results showed great potential to develop porustobart as a…